Mecab

Mecab tablet is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of Mecab has not been clearly identified, but may be related to its sedative properties. Mecab does not directly relax tense skeletal muscles in man.

Route of Administration: Oral
Methocarbamol 500 mg- Adults:
Initial dosage: 3 tablets q.i.d.
Maintenance dosage: 2 tablets q.i.d.
Methocarbamol 750 mg- Adults:
Initial dosage: 2 tablets q.i.d.
Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.
Six grams a day are recommended for the first 48 to 72 hours of treatment (for severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.
Pediatric Use
: Safety and effectiveness of Methocarbamol in pediatric patients below the age of 16 have not been established.

Adverse reactions reported coincident with the administration of Mecab include:
Body as a whole
: Anaphylactic reaction, angioneurotic edema, fever, headache
Cardiovascular system
: Bradycardia, flushing, hypotension, syncope, thrombo- phlebitis
Digestive system
: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting
Hemic and lymphatic system
: Leukopenia
Immune system
: Hypersensitivity reactions
Nervous system
: Amnesia, confusion, Diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo
Skin and special senses
: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria.

Patients should be cautioned that Mecab may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery because Mecab may possess a general CNS-depressants effect. Patients should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Mecab has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to Mecab. Therefore, Mecab should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards.

The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity. This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells. Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.